On Thursday, in the course of current trade, Shares of GoPro, Inc. (NASDAQ:GPRO), dropped -0.86%, and is now trading at $58.52.
GoPro, declared that it will present at the 35th Annual Piper Jaffray Consumer Conference on Wednesday, June 10, 2015.
GoPro, Inc. develops hardware and software solutions to alleviate consumer pain points associated with capturing, managing, sharing, and enjoying engaging content. The company offers HERO line of capture devices, such as cameras; premium accessories, counting battery BacPac, smart remote, and LCD touch BacPac accessories; and mounts comprising equipment-based mounts compriseing of helmet, handlebar, roll bar, and grip and tripod mounts that enable consumers to capture content while engaged in a range of activities, in addition to mounts that enable customers to wear the mount on their bodies, such as wrist housings, chest harnesses, and head straps.
During an Afternoon trade, Shares of Ascena Retail Group Inc. (NASDAQ:ASNA), gained 0.28%, and is now trading at $15.86.
Ascena Retail Group, will be presenting at Piper Jaffray 35th Annual Consumer Conference at The New York Palace Hotel in New York, NY on Wednesday, June 10, 2015 at 9:05 am ET.
Ascena Retail Group, Inc., through its auxiliaries, operates as a specialty retailer of apparel for women, and tween girls and boys. It operates through five segments: Justice, Lane Bryant, maurices, dressbarn, and Catherines segments.
Shares of Celgene Corporation (NASDAQ:CELG), during its Thursday’s current trading session fell -2.17%, and is now trading at $110.24.
Celgene International Sàrl, a wholly-owned partner of Celgene Corporation, declared that data from 11 abstracts (two oral presentations, six poster presentations and three published in The Abstract Book) evaluating Celgene investigational and marketed products will be presented at the European League Against Rheumatism (EULAR) Annual Congress in Rome, Italy, June 10 – 13, 2015. The data will comprise the latest research findings on Otezla® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in psoriatic arthritis and plaque psoriasis, in addition to CC-220, an investigational immunomodulatory compound for systemic lupus erythematosus (lupus).
Among the data presented will be long-term (104-week) results from Celgene’s PALACE program, counting pooled results of three phase III trials (PALACE 1, 2 and 3) assessing the effects of OTEZLA on two distinct manifestations of psoriatic arthritis – enthesitis (inflammation at sites where tendons or ligaments insert into bone) and dactylitis (inflammation of an entire digit). Additional analyses of PALACE trials will evaluate long-term safety and efficacy of OTEZLA in patients with active psoriatic arthritis, in addition to the impact of OTEZLA on work productivity and physical function in these patients.
Data will also be presented on the effect of CC-220 on blood cell levels of Ikaros and Aiolos – transcription factors that, when mutated, are associated with an raised risk of systemic lupus erythematosus. The presentation will comprise phase I data on the impact of CC-220 on the immune response in healthy volunteers. Additional preclinical studies on CC-220 in lupus will be presented.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Finally, AXIS Capital Holdings Limited (NYSE:AXS), lost -1.71% Thursday.
PartnerRe Ltd. (PRE) , declared that, together with AXIS Capital Holdings Limited, (AXS), they will be filing with the U.S. Securities and Exchange Commission (SEC) a joint registration statement on Form S-4, which will comprise a joint proxy statement of AXIS Capital and PartnerRe, in connection with the definitive amalgamation agreement that the companies declared on January 25, 2015, and subsequently amended.
PartnerRe also filed with the SEC a joint investor presentation outlining the noteworthy planned and financial benefits of the merger between the Company and AXIS Capital, in addition to a PartnerRe presentation that clearly demonstrates that EXOR’s offer for the Company is opportunistic and unacceptable on price and terms.
AXIS Capital Holdings Limited, together with its auxiliaries, provides insurance and treaty reinsurance products Worldwide. The company operates through Insurance and Reinsurance segments. The Insurance segment provides property insurance for commercial buildings, residential premises, construction projects, and onshore energy installations; marine insurance covering offshore energy, cargo, liability, recreational marine, fine art, specie, hull, and war; and terrorism, aviation, credit and political risk, and liability insurance.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
